Symbols / FHTX Stock $4.34 +0.23% Foghorn Therapeutics Inc.
FHTX (Stock) Chart
Stock Fundamentals
|
|
|
|
|
|
About
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing therapies for mutant; non-small cell lung; endometrial, cervical, ovarian, and bladder cancer; and diffuse large B-cell lymphoma, as well as various acute myeloid leukemia and myelodysplastic syndrome. The company has collaboration agreement with Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Ratings
Current target
$4.24
Low
$9.00
High
$14.00
Mean
$11.44
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-12 | reit | Wedbush | Outperform → Outperform | $10 |
| 2026-03-10 | reit | HC Wainwright & Co. | Buy → Buy | $13 |
| 2026-02-17 | main | Jefferies | Buy → Buy | $12 |
| 2025-12-18 | init | BTIG | — → Buy | $11 |
| 2025-12-04 | init | Stifel | — → Buy | $12 |
| 2025-11-07 | init | Guggenheim | — → Buy | $12 |
| 2025-05-15 | reit | JMP Securities | Market Outperform → Market Outperform | $9 |
| 2025-04-30 | reit | JMP Securities | Market Outperform → Market Outperform | $9 |
| 2025-04-30 | reit | HC Wainwright & Co. | Buy → Buy | $13 |
| 2025-04-23 | init | JMP Securities | — → Market Outperform | $9 |
| 2025-03-07 | reit | HC Wainwright & Co. | Buy → Buy | $13 |
| 2025-01-30 | init | B. Riley Securities | — → Buy | $10 |
| 2024-12-17 | reit | HC Wainwright & Co. | Buy → Buy | $13 |
| 2024-12-16 | main | Jefferies | Buy → Buy | $14 |
| 2024-09-24 | main | Morgan Stanley | Equal-Weight → Equal-Weight | $9 |
| 2024-09-03 | init | Jefferies | — → Buy | $18 |
| 2024-08-19 | init | Evercore ISI Group | — → Outperform | $20 |
| 2024-08-12 | reit | HC Wainwright & Co. | Buy → Buy | $20 |
| 2024-08-09 | reit | Wedbush | Outperform → Outperform | $13 |
| 2024-05-07 | reit | HC Wainwright & Co. | Buy → Buy | $20 |
- Biotech Foghorn lines up three May oncology investor events - Stock Titan ue, 12 May 2026 11
- Foghorn Therapeutics Inc. (FHTX) may report negative earnings: Know the trend ahead of Q1 release - MSN Mon, 11 May 2026 20
- Analysts Have Made A Financial Statement On Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) First-Quarter Report - simplywall.st Mon, 11 May 2026 15
- The Foghorn Therapeutics Inc. (NASDAQ:FHTX) First-Quarter Results Are Out And Analysts Have Published New Forecasts - Yahoo Finance Mon, 11 May 2026 15
- Number of shareholders of Foghorn Therapeutics Inc. – NASDAQ:FHTX - TradingView hu, 07 May 2026 14
- Foghorn says lead lung cancer trial stays on track, funded into 2028 - Stock Titan hu, 07 May 2026 11
- Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance hu, 07 May 2026 12
- Foghorn Therapeutics (Nasdaq: FHTX) details Q1 2026 results and oncology pipeline - Stock Titan hu, 07 May 2026 11
- Foghorn Therapeutics Inc. (FHTX) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance Wed, 11 Mar 2026 07
- Foghorn Therapeutics (NASDAQ: FHTX) trims expenses, raises $50M in Q1 2026 - Stock Titan hu, 07 May 2026 11
- FMR LLC reports 11.6% ownership in Foghorn Therapeutics (NASDAQ: FHTX) - Stock Titan Wed, 06 May 2026 15
- Executive pay, major holders and votes in Foghorn (NASDAQ: FHTX) 2026 proxy - Stock Titan hu, 30 Apr 2026 11
- Foghorn Therapeutics (FHTX): Forecast 28.8% Revenue Growth Challenges Ongoing Loss Narrative - Yahoo Finance Wed, 05 Nov 2025 08
- New lung, breast and blood cancer data put Foghorn programs at AACR - Stock Titan hu, 09 Apr 2026 07
- Foghorn Therapeutics Highlights Q1 Progress in Oncology Pipeline - TipRanks hu, 07 May 2026 12
Insider Transactions
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
30.91
+36.75%
|
22.60
-33.83%
|
34.16
+77.63%
|
19.23
|
| Operating Revenue |
|
30.91
+36.75%
|
22.60
-33.83%
|
34.16
+77.63%
|
19.23
|
| Operating Expense |
|
113.02
-8.03%
|
122.89
-13.50%
|
142.06
+4.18%
|
136.37
|
| Research And Development |
|
85.47
-9.59%
|
94.53
-13.82%
|
109.69
+3.85%
|
105.62
|
| Selling General And Administration |
|
27.55
-2.85%
|
28.36
-12.40%
|
32.37
+5.29%
|
30.75
|
| General And Administrative Expense |
|
27.55
-2.85%
|
28.36
-12.40%
|
32.37
+5.29%
|
30.75
|
| Salaries And Wages |
|
17.41
+1.69%
|
17.12
-16.73%
|
20.57
+12.73%
|
18.24
|
| Other Gand A |
|
10.13
-9.78%
|
11.23
-4.84%
|
11.81
-5.58%
|
12.50
|
| Total Expenses |
|
113.02
-8.03%
|
122.89
-13.50%
|
142.06
+4.18%
|
136.37
|
| Operating Income |
|
-82.11
+18.13%
|
-100.28
+7.06%
|
-107.91
+7.88%
|
-117.14
|
| Total Operating Income As Reported |
|
-86.39
+15.87%
|
-102.68
+4.84%
|
-107.91
+7.88%
|
-117.14
|
| EBITDA |
|
-78.78
+18.93%
|
-97.17
+6.98%
|
-104.45
+8.22%
|
-113.82
|
| Normalized EBITDA |
|
-74.49
+21.39%
|
-94.77
+9.27%
|
-104.45
+8.22%
|
-113.82
|
| Reconciled Depreciation |
|
3.33
+6.79%
|
3.12
-9.59%
|
3.45
+3.91%
|
3.32
|
| EBIT |
|
-82.11
+18.13%
|
-100.28
+7.06%
|
-107.91
+7.88%
|
-117.14
|
| Total Unusual Items |
|
-4.28
-78.57%
|
-2.40
|
0.00
|
0.00
|
| Total Unusual Items Excluding Goodwill |
|
-4.28
-78.57%
|
-2.40
|
0.00
|
0.00
|
| Special Income Charges |
|
-4.28
-78.57%
|
-2.40
|
0.00
|
0.00
|
| Other Special Charges |
|
-1.63
|
—
|
—
|
—
|
| Impairment Of Capital Assets |
|
—
|
2.40
|
0.00
|
—
|
| Write Off |
|
5.91
+146.62%
|
2.40
|
0.00
|
—
|
| Net Income |
|
-74.28
+14.24%
|
-86.62
+11.99%
|
-98.43
+9.60%
|
-108.88
|
| Pretax Income |
|
-74.28
+14.24%
|
-86.62
+8.05%
|
-94.20
+13.48%
|
-108.88
|
| Net Non Operating Interest Income Expense |
|
8.74
-26.51%
|
11.90
+9.43%
|
10.88
+91.63%
|
5.67
|
| Interest Expense Non Operating |
|
—
|
—
|
—
|
0.00
|
| Net Interest Income |
|
8.74
-26.51%
|
11.90
+9.43%
|
10.88
+91.63%
|
5.67
|
| Interest Expense |
|
—
|
—
|
—
|
0.00
|
| Interest Income Non Operating |
|
8.74
-26.51%
|
11.90
+9.43%
|
10.88
+91.63%
|
5.67
|
| Interest Income |
|
8.74
-26.51%
|
11.90
+9.43%
|
10.88
+91.63%
|
5.67
|
| Other Income Expense |
|
-0.92
-152.18%
|
1.76
-37.65%
|
2.83
+9.73%
|
2.58
|
| Other Non Operating Income Expenses |
|
3.36
-19.26%
|
4.16
+47.05%
|
2.83
+9.73%
|
2.58
|
| Tax Provision |
|
—
|
0.00
-100.00%
|
4.23
|
0.00
|
| Tax Rate For Calcs |
|
0.00
|
0.00
-100.00%
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-74.28
+14.24%
|
-86.62
+11.99%
|
-98.43
+9.60%
|
-108.88
|
| Net Income From Continuing Operation Net Minority Interest |
|
-74.28
+14.24%
|
-86.62
+11.99%
|
-98.43
+9.60%
|
-108.88
|
| Net Income From Continuing And Discontinued Operation |
|
-74.28
+14.24%
|
-86.62
+11.99%
|
-98.43
+9.60%
|
-108.88
|
| Net Income Continuous Operations |
|
-74.28
+14.24%
|
-86.62
+11.99%
|
-98.43
+9.60%
|
-108.88
|
| Normalized Income |
|
-70.00
+16.89%
|
-84.22
+14.43%
|
-98.43
+9.60%
|
-108.88
|
| Net Income Common Stockholders |
|
-74.28
+14.24%
|
-86.62
+11.99%
|
-98.43
+9.60%
|
-108.88
|
| Diluted EPS |
|
—
|
-1.58
+32.48%
|
-2.34
+10.69%
|
-2.62
|
| Basic EPS |
|
—
|
-1.58
+32.48%
|
-2.34
+10.69%
|
-2.62
|
| Basic Average Shares |
|
—
|
54.90
+30.79%
|
41.97
+0.92%
|
41.59
|
| Diluted Average Shares |
|
—
|
54.90
+30.79%
|
41.97
+0.92%
|
41.59
|
| Diluted NI Availto Com Stockholders |
|
-74.28
+14.24%
|
-86.62
+11.99%
|
-98.43
+9.60%
|
-108.88
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
198.10
-30.24%
|
283.98
-0.68%
|
285.92
-29.38%
|
404.88
|
| Current Assets |
|
163.24
-34.60%
|
249.60
+3.92%
|
240.18
-31.65%
|
351.40
|
| Cash Cash Equivalents And Short Term Investments |
|
158.89
-34.81%
|
243.75
+4.14%
|
234.06
-32.31%
|
345.80
|
| Cash And Cash Equivalents |
|
80.88
+45.84%
|
55.45
-30.97%
|
80.34
+53.86%
|
52.21
|
| Other Short Term Investments |
|
78.02
-58.57%
|
188.29
+22.49%
|
153.72
-47.64%
|
293.58
|
| Receivables |
|
—
|
—
|
—
|
0.00
|
| Accounts Receivable |
|
—
|
—
|
—
|
0.00
|
| Prepaid Assets |
|
—
|
—
|
—
|
—
|
| Restricted Cash |
|
1.25
|
0.00
|
—
|
—
|
| Other Current Assets |
|
3.09
-47.20%
|
5.85
-4.41%
|
6.12
+9.34%
|
5.60
|
| Total Non Current Assets |
|
34.87
+1.42%
|
34.38
-24.83%
|
45.73
-14.49%
|
53.48
|
| Net PPE |
|
32.86
+0.79%
|
32.60
-24.02%
|
42.91
-13.13%
|
49.40
|
| Gross PPE |
|
39.87
-16.40%
|
47.69
-13.18%
|
54.93
-5.31%
|
58.01
|
| Accumulated Depreciation |
|
-7.00
+53.56%
|
-15.08
-25.52%
|
-12.02
-39.55%
|
-8.61
|
| Properties |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Buildings And Improvements |
|
30.95
+36.69%
|
22.64
-24.42%
|
29.96
-12.12%
|
34.09
|
| Machinery Furniture Equipment |
|
0.89
-2.32%
|
0.91
-2.58%
|
0.93
+1.64%
|
0.92
|
| Other Properties |
|
8.04
+12.87%
|
7.12
+4.63%
|
6.80
+15.64%
|
5.88
|
| Leases |
|
0.00
-100.00%
|
17.02
-1.25%
|
17.24
+0.68%
|
17.12
|
| Other Non Current Assets |
|
2.00
+12.84%
|
1.78
-37.09%
|
2.82
-30.93%
|
4.09
|
| Total Liabilities Net Minority Interest |
|
306.60
-6.95%
|
329.51
-9.25%
|
363.11
-10.29%
|
404.77
|
| Current Liabilities |
|
59.74
-10.82%
|
66.99
+14.64%
|
58.44
+5.85%
|
55.20
|
| Payables And Accrued Expenses |
|
9.30
+22.83%
|
7.57
-31.06%
|
10.98
-3.25%
|
11.35
|
| Payables |
|
4.27
+12.71%
|
3.79
-45.41%
|
6.93
+28.08%
|
5.41
|
| Accounts Payable |
|
4.27
+12.71%
|
3.79
-39.54%
|
6.26
+15.63%
|
5.41
|
| Current Accrued Expenses |
|
5.04
+32.95%
|
3.79
-6.49%
|
4.05
-31.80%
|
5.94
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
5.92
+24.86%
|
4.74
+9.09%
|
4.35
-8.35%
|
4.74
|
| Total Tax Payable |
|
—
|
0.00
-100.00%
|
0.67
|
0.00
|
| Income Tax Payable |
|
—
|
0.00
-100.00%
|
0.67
|
0.00
|
| Current Debt And Capital Lease Obligation |
|
0.92
-89.82%
|
9.07
+6.45%
|
8.52
+42.68%
|
5.97
|
| Current Capital Lease Obligation |
|
0.92
-89.82%
|
9.07
+6.45%
|
8.52
+42.68%
|
5.97
|
| Current Deferred Liabilities |
|
43.19
-5.29%
|
45.61
+32.00%
|
34.55
+5.27%
|
32.82
|
| Current Deferred Revenue |
|
43.19
-5.29%
|
45.61
+32.00%
|
34.55
+5.27%
|
32.82
|
| Other Current Liabilities |
|
0.40
+39900.00%
|
0.00
-97.22%
|
0.04
-88.68%
|
0.32
|
| Total Non Current Liabilities Net Minority Interest |
|
246.87
-5.96%
|
262.52
-13.83%
|
304.67
-12.84%
|
349.57
|
| Long Term Debt And Capital Lease Obligation |
|
40.35
+43.77%
|
28.06
-23.23%
|
36.55
-19.72%
|
45.54
|
| Long Term Capital Lease Obligation |
|
40.35
+43.77%
|
28.06
-23.23%
|
36.55
-19.72%
|
45.54
|
| Non Current Deferred Liabilities |
|
205.96
-12.15%
|
234.46
-12.55%
|
268.12
-11.80%
|
304.00
|
| Non Current Deferred Revenue |
|
205.96
-12.15%
|
234.46
-12.55%
|
268.12
-11.80%
|
304.00
|
| Other Non Current Liabilities |
|
0.56
|
—
|
—
|
0.03
|
| Stockholders Equity |
|
-108.50
-138.31%
|
-45.53
+41.02%
|
-77.19
-69019.64%
|
0.11
|
| Common Stock Equity |
|
-108.50
-138.31%
|
-45.53
+41.02%
|
-77.19
-69019.64%
|
0.11
|
| Capital Stock |
|
0.01
+0.00%
|
0.01
+50.00%
|
0.00
+0.00%
|
0.00
|
| Common Stock |
|
0.01
+0.00%
|
0.01
+50.00%
|
0.00
+0.00%
|
0.00
|
| Preferred Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Share Issued |
|
56.66
+1.91%
|
55.59
+31.48%
|
42.28
+1.14%
|
41.80
|
| Ordinary Shares Number |
|
56.66
+1.91%
|
55.59
+31.48%
|
42.28
+1.14%
|
41.80
|
| Additional Paid In Capital |
|
523.94
+2.23%
|
512.51
+29.69%
|
395.20
+4.76%
|
377.23
|
| Retained Earnings |
|
-632.47
-13.31%
|
-558.18
-18.37%
|
-471.56
-26.38%
|
-373.14
|
| Gains Losses Not Affecting Retained Earnings |
|
0.02
-82.22%
|
0.14
+116.34%
|
-0.83
+79.28%
|
-3.99
|
| Other Equity Adjustments |
|
0.02
-82.22%
|
0.14
+116.34%
|
-0.83
+79.28%
|
-3.99
|
| Total Equity Gross Minority Interest |
|
-108.50
-138.31%
|
-45.53
+41.02%
|
-77.19
-69019.64%
|
0.11
|
| Total Capitalization |
|
-108.50
-138.31%
|
-45.53
+41.02%
|
-77.19
-69019.64%
|
0.11
|
| Working Capital |
|
103.50
-43.32%
|
182.61
+0.48%
|
181.75
-38.64%
|
296.19
|
| Invested Capital |
|
-108.50
-138.31%
|
-45.53
+41.02%
|
-77.19
-69019.64%
|
0.11
|
| Total Debt |
|
41.27
+11.15%
|
37.13
-17.62%
|
45.07
-12.49%
|
51.51
|
| Capital Lease Obligations |
|
41.27
+11.15%
|
37.13
-17.62%
|
45.07
-12.49%
|
51.51
|
| Net Tangible Assets |
|
-108.50
-138.31%
|
-45.53
+41.02%
|
-77.19
-69019.64%
|
0.11
|
| Tangible Book Value |
|
-108.50
-138.31%
|
-45.53
+41.02%
|
-77.19
-69019.64%
|
0.11
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-86.10
+14.25%
|
-100.41
+14.99%
|
-118.11
-161.00%
|
193.61
|
| Cash Flow From Continuing Operating Activities |
|
-86.10
+14.25%
|
-100.41
+14.99%
|
-118.11
-161.00%
|
193.61
|
| Net Income From Continuing Operations |
|
-74.28
+14.24%
|
-86.62
+11.99%
|
-98.43
+9.60%
|
-108.88
|
| Depreciation Amortization Depletion |
|
3.33
+6.79%
|
3.12
-9.59%
|
3.45
+3.91%
|
3.32
|
| Depreciation |
|
—
|
—
|
—
|
3.32
|
| Depreciation And Amortization |
|
3.33
+6.79%
|
3.12
-9.59%
|
3.45
+3.91%
|
3.32
|
| Other Non Cash Items |
|
2.57
-54.70%
|
5.68
+9.06%
|
5.21
+13.76%
|
4.58
|
| Stock Based Compensation |
|
10.40
-12.56%
|
11.89
-26.52%
|
16.19
+12.90%
|
14.34
|
| Asset Impairment Charge |
|
5.91
+146.62%
|
2.40
|
0.00
|
—
|
| Operating Gains Losses |
|
0.03
|
—
|
0.00
-50.00%
|
0.01
|
| Gain Loss On Sale Of PPE |
|
0.03
|
0.00
-100.00%
|
0.00
-50.00%
|
0.01
|
| Change In Working Capital |
|
-32.14
+0.39%
|
-32.27
+22.95%
|
-41.88
-114.87%
|
281.55
|
| Change In Receivables |
|
—
|
—
|
0.00
-100.00%
|
300.00
|
| Changes In Account Receivables |
|
—
|
—
|
—
|
300.00
|
| Change In Prepaid Assets |
|
2.83
+114.65%
|
1.32
+77.73%
|
0.74
+341.37%
|
-0.31
|
| Change In Payables And Accrued Expense |
|
2.69
+188.35%
|
-3.04
-219.56%
|
-0.95
-131.13%
|
3.06
|
| Change In Accrued Expense |
|
2.20
+490.78%
|
-0.56
+68.61%
|
-1.80
-224.71%
|
1.44
|
| Change In Payable |
|
0.48
+119.43%
|
-2.48
-392.55%
|
0.85
-47.58%
|
1.61
|
| Change In Account Payable |
|
0.48
+119.43%
|
-2.48
-392.55%
|
0.85
-47.58%
|
1.61
|
| Change In Other Working Capital |
|
-30.91
-36.75%
|
-22.60
+33.83%
|
-34.16
-140.07%
|
-14.23
|
| Change In Other Current Liabilities |
|
-6.74
+15.10%
|
-7.94
-5.70%
|
-7.51
-7.73%
|
-6.97
|
| Investing Cash Flow |
|
112.04
+474.67%
|
-29.90
-120.70%
|
144.45
+159.12%
|
-244.32
|
| Cash Flow From Continuing Investing Activities |
|
112.04
+474.67%
|
-29.90
-120.70%
|
144.45
+159.12%
|
-244.32
|
| Net PPE Purchase And Sale |
|
-0.05
+94.48%
|
-0.91
+25.98%
|
-1.22
-1.16%
|
-1.21
|
| Purchase Of PPE |
|
-0.05
+94.48%
|
-0.91
+25.98%
|
-1.22
-1.16%
|
-1.21
|
| Sale Of PPE |
|
—
|
—
|
—
|
—
|
| Capital Expenditure |
|
-0.05
+94.48%
|
-0.91
+25.98%
|
-1.22
-1.16%
|
-1.21
|
| Net Investment Purchase And Sale |
|
112.09
+486.54%
|
-29.00
-119.91%
|
145.67
+159.92%
|
-243.11
|
| Purchase Of Investment |
|
-131.25
+49.80%
|
-261.47
-253.81%
|
-73.90
+81.95%
|
-409.35
|
| Sale Of Investment |
|
243.34
+4.67%
|
232.47
+5.87%
|
219.57
+32.09%
|
166.23
|
| Financing Cash Flow |
|
1.02
-99.03%
|
105.43
+5829.58%
|
1.78
+0.85%
|
1.76
|
| Cash Flow From Continuing Financing Activities |
|
1.02
-99.03%
|
105.43
+5829.58%
|
1.78
+0.85%
|
1.76
|
| Net Issuance Payments Of Debt |
|
—
|
—
|
—
|
0.00
|
| Issuance Of Debt |
|
—
|
—
|
—
|
—
|
| Repayment Of Debt |
|
—
|
—
|
—
|
0.00
|
| Long Term Debt Issuance |
|
—
|
—
|
—
|
—
|
| Long Term Debt Payments |
|
—
|
—
|
—
|
0.00
|
| Net Long Term Debt Issuance |
|
—
|
—
|
—
|
0.00
|
| Net Common Stock Issuance |
|
0.54
-99.48%
|
103.40
|
0.00
|
0.00
|
| Proceeds From Stock Option Exercised |
|
0.48
-81.51%
|
2.61
+46.91%
|
1.78
+0.85%
|
1.76
|
| Net Other Financing Charges |
|
—
|
-0.58
|
—
|
—
|
| Changes In Cash |
|
26.96
+208.37%
|
-24.88
-188.48%
|
28.12
+157.45%
|
-48.95
|
| Beginning Cash Position |
|
57.16
-30.33%
|
82.04
+52.15%
|
53.92
-47.58%
|
102.87
|
| End Cash Position |
|
84.13
+47.17%
|
57.16
-30.33%
|
82.04
+52.15%
|
53.92
|
| Free Cash Flow |
|
-86.15
+14.97%
|
-101.31
+15.10%
|
-119.33
-162.02%
|
192.40
|
| Interest Paid Supplemental Data |
|
—
|
—
|
—
|
0.00
|
| Income Tax Paid Supplemental Data |
|
0.01
-98.95%
|
0.86
-75.78%
|
3.55
|
0.00
|
| Amortization Of Securities |
|
-1.93
+58.25%
|
-4.61
-74.01%
|
-2.65
-104.71%
|
-1.29
|
| Common Stock Issuance |
|
0.54
-99.48%
|
103.40
|
0.00
|
0.00
|
| Issuance Of Capital Stock |
|
0.54
-99.48%
|
103.40
|
0.00
|
0.00
|
| Net Preferred Stock Issuance |
|
—
|
—
|
—
|
—
|
| Preferred Stock Issuance |
|
—
|
—
|
—
|
—
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 10-Q2026-05-07 View
- 8-K2026-05-07 View
- 8-K2026-04-21 View
- 42026-04-13 View
- 10-K2026-03-11 View
- 8-K2026-03-11 View
- 42026-02-24 View
- 8-K2026-02-23 View
- 42026-02-06 View
- 42026-02-02 View
- 42026-02-02 View
- 42026-02-02 View
- 42026-02-02 View
- 42026-02-02 View
- 42026-01-15 View
- 8-K2026-01-12 View
- 8-K2025-12-04 View
- 42025-11-17 View
- 8-K2025-11-07 View
- 10-Q2025-11-05 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|